Literature DB >> 22809348

Beyond comparing means: the usefulness of analyzing interindividual variation in gene expression for identifying genes associated with cancer development.

Ivan P Gorlov1, Jinyoung Byun, Hongya Zhao, Christopher J Logothetis, Olga Y Gorlova.   

Abstract

Identifying genes associated with cancer development is typically accomplished by comparing mean expression values in normal and tumor tissues, which identifies differentially expressed (DE) genes. Interindividual variation (IV) in gene expression is indirectly included in DE gene identification because given the same absolute differences in means, genes with lower variance tend to have lower p-values. We explored the direct use of IV in gene expression to identify candidate genes associated with cancer development. We focused on prostate (PCa) and lung (LC) cancers and compared IV in the expression level of genes shown to be cancer related with that in all other genes in the human genome. Compared with all those other genes, cancer-related genes tended to have greater IV in normal tissues and a greater increase in IV during the transition from normal to tumorous tissue. Genes without significantly different mean expression values between tumor and normal tissues but with greater IV in tumor than in normal tissue (note: the DE-based approach completely ignores those genes) had stronger associations with clinically important features like Gleason score in PCa or tumor histology in LC than all other genes were. Our results suggest that analyzing IV in gene expression level is useful in identifying novel candidate genes associated with cancer development.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22809348      PMCID: PMC3893106          DOI: 10.1142/S0219720012410132

Source DB:  PubMed          Journal:  J Bioinform Comput Biol        ISSN: 0219-7200            Impact factor:   1.122


  24 in total

1.  Breast cancer heterogeneity may explain peaks in recurrence.

Authors:  Donald Berry
Journal:  Int J Surg       Date:  2005-12-12       Impact factor: 6.071

Review 2.  Genetic and epigenetic heterogeneity in cancer: a genome-centric perspective.

Authors:  Henry H Q Heng; Steven W Bremer; Joshua B Stevens; Karen J Ye; Guo Liu; Christine J Ye
Journal:  J Cell Physiol       Date:  2009-09       Impact factor: 6.384

3.  [Gleason's score: update in 2008].

Authors:  Vincent Molinié
Journal:  Ann Pathol       Date:  2008-10-08       Impact factor: 0.407

4.  Watchful waiting beats androgen deprivation therapy in early prostate cancer.

Authors:  Vicki Brower
Journal:  J Natl Cancer Inst       Date:  2008-10-28       Impact factor: 13.506

Review 5.  Gene expression profiling in the developing prostate.

Authors:  Colin C Pritchard; Peter S Nelson
Journal:  Differentiation       Date:  2008-05-07       Impact factor: 3.880

6.  Heterogeneity of expression of cytokeratin subtypes in squamous cell carcinoma of the lung: with special reference to CK14 overexpression in cancer of high-proliferative and lymphogenous metastatic potential.

Authors:  Futoshi Tsubokawa; Takashi Nishisaka; Yukio Takeshima; Kouki Inai
Journal:  Pathol Int       Date:  2002-04       Impact factor: 2.534

Review 7.  Lung cancer management in 2010.

Authors:  Apar Kishor Ganti; Chao H Huang; Mark A Klein; Sean Keefe; Michael J Kelley
Journal:  Oncology (Williston Park)       Date:  2011-01       Impact factor: 2.990

8.  Heterogeneity in prostate cancer: prostate specific antigen (PSA) and DNA cytophotometry.

Authors:  F Steffen Krause; Gerhard Feil; Karl-Horst Bichler; Karl M Schrott; Ziya Y Akcetin; Dirk G Engehausen
Journal:  Anticancer Res       Date:  2005 May-Jun       Impact factor: 2.480

Review 9.  Alternative splicing and biological heterogeneity in prostate cancer.

Authors:  Prabhakar Rajan; David J Elliott; Craig N Robson; Hing Y Leung
Journal:  Nat Rev Urol       Date:  2009-08       Impact factor: 14.432

10.  GWAS meets microarray: are the results of genome-wide association studies and gene-expression profiling consistent? Prostate cancer as an example.

Authors:  Ivan P Gorlov; Gary E Gallick; Olga Y Gorlova; Christopher Amos; Christopher J Logothetis
Journal:  PLoS One       Date:  2009-08-04       Impact factor: 3.240

View more
  5 in total

1.  Identification of differentially distributed gene expression and distinct sets of cancer-related genes identified by changes in mean and variability.

Authors:  Aedan G K Roberts; Daniel R Catchpoole; Paul J Kennedy
Journal:  NAR Genom Bioinform       Date:  2022-01-14

2.  How to get the most from microarray data: advice from reverse genomics.

Authors:  Ivan P Gorlov; Ji-Yeon Yang; Jinyoung Byun; Christopher Logothetis; Olga Y Gorlova; Kim-Anh Do; Christopher Amos
Journal:  BMC Genomics       Date:  2014-03-21       Impact factor: 3.969

3.  A lung cancer risk classifier comprising genome maintenance genes measured in normal bronchial epithelial cells.

Authors:  Jiyoun Yeo; Erin L Crawford; Xiaolu Zhang; Sadik Khuder; Tian Chen; Albert Levin; Thomas M Blomquist; James C Willey
Journal:  BMC Cancer       Date:  2017-05-02       Impact factor: 4.430

4.  Integration of copy number and transcriptomics provides risk stratification in prostate cancer: A discovery and validation cohort study.

Authors:  H Ross-Adams; A D Lamb; M J Dunning; S Halim; J Lindberg; C M Massie; L A Egevad; R Russell; A Ramos-Montoya; S L Vowler; N L Sharma; J Kay; H Whitaker; J Clark; R Hurst; V J Gnanapragasam; N C Shah; A Y Warren; C S Cooper; A G Lynch; R Stark; I G Mills; H Grönberg; D E Neal
Journal:  EBioMedicine       Date:  2015-07-29       Impact factor: 8.143

5.  The activation of OR51E1 causes growth suppression of human prostate cancer cells.

Authors:  Désirée Maßberg; Nikolina Jovancevic; Anne Offermann; Annika Simon; Aria Baniahmad; Sven Perner; Thanakorn Pungsrinont; Katarina Luko; Stathis Philippou; Burkhard Ubrig; Markus Heiland; Lea Weber; Janine Altmüller; Christian Becker; Günter Gisselmann; Lian Gelis; Hanns Hatt
Journal:  Oncotarget       Date:  2016-07-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.